NASDAQ:PRQR

ProQR (PRQR) Eyes Next Move After Holiday Ahead of AX-0810 Data
····

ProQR (PRQR) Eyes Next Move After Holiday Ahead of AX-0810 Data

ProQR shares closed at $1.56 on May 22, up 8.3%, then slipped to $1.54 after hours, finishing the week down 1.9%. The company expects AX-0810 target-engagement data in Q2 and has prioritized biliary atresia for its next development step. ProQR ended March with €81.1 million in cash, enough to fund operations into mid-2027. The annual meeting is set for June 2 in Amsterdam.
May 24, 2026

Stock Market Today

  • Genomic Test Could Spare Millions of Breast Cancer Patients Chemotherapy, Landmark Study Finds
    May 29, 2026, 8:16 PM EDT. A landmark study reveals that millions of breast cancer patients could safely skip chemotherapy thanks to the Prosigna genomic test, which analyses tumor genes to assess recurrence risk. The international OPTIMA trial, involving 4,429 patients, showed a 93.7% five-year cancer-free survival rate for those who avoided chemotherapy, nearly matching the 94.9% rate for those treated with it. Karen Bonham, a trial participant, described her relief upon learning she would not need chemotherapy, attributing her cancer-free status nine years post-diagnosis to the test's guidance. Experts hail the findings as gamechanging, potentially transforming breast cancer treatment by reducing unnecessary chemotherapy and its side effects, while maintaining patient safety.